Acrobiosystems Co Ltd
SZSE:301080
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
31.53
66.85
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Acrobiosystems Co Ltd
Acrobiosystems Co Ltd
Accrued Liabilities
Acrobiosystems Co Ltd
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Acrobiosystems Co Ltd
SZSE:301080
|
Accrued Liabilities
¥37.7m
|
CAGR 3-Years
60%
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Accrued Liabilities
¥2.6B
|
CAGR 3-Years
49%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Accrued Liabilities
¥134.4m
|
CAGR 3-Years
57%
|
CAGR 5-Years
81%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Accrued Liabilities
¥268.5m
|
CAGR 3-Years
37%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Accrued Liabilities
¥164.1m
|
CAGR 3-Years
50%
|
CAGR 5-Years
30%
|
CAGR 10-Years
19%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Accrued Liabilities
¥325.2m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
85%
|
CAGR 10-Years
60%
|
|
Acrobiosystems Co Ltd
Glance View
ACROBiosystems Co., Ltd. engages in the development of biomedicine and bio-protein technology. The company is headquartered in Beijing, Beijing and currently employs 397 full-time employees. The company went IPO on 2021-10-18. The firm's main products are recombinant proteins and detection services, as well as kits, antibodies, fillers, culture media and other related products. The firm's main products and services are applied to research and development (R&D) and production links such as early drug discovery and verification, drug screening and optimization, development and optimization of diagnostic reagents, preclinical and clinical trials, drug production process and process control (CMC) of tumors, autoimmune diseases, cardiovascular diseases, infectious diseases and other diseases.
See Also
What is Acrobiosystems Co Ltd's Accrued Liabilities?
Accrued Liabilities
37.7m
CNY
Based on the financial report for Dec 31, 2023, Acrobiosystems Co Ltd's Accrued Liabilities amounts to 37.7m CNY.
What is Acrobiosystems Co Ltd's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
44%
Over the last year, the Accrued Liabilities growth was 21%. The average annual Accrued Liabilities growth rates for Acrobiosystems Co Ltd have been 60% over the past three years , 44% over the past five years .
You don't have any saved screeners yet
